Marksans Pharma Limited (NSE:MARKSANS)
India · Delayed Price · Currency is INR | Market Cap | 139.44B +68.2% |
| Revenue (ttm) | 33.92B +24.2% |
| Net Income | 5.60B +59.2% |
| EPS | 12.35 +59.3% |
| Shares Out | 453.16M |
| PE Ratio | 24.91 |
| Forward PE | 22.82 |
| Dividend | 0.90 (0.29%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 443,769 |
| Open | 305.60 |
| Previous Close | 303.75 |
| Day's Range | 305.20 - 313.50 |
| 52-Week Range | 155.00 - 350.95 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 324.33 (+5.41%) |
| Earnings Date | Nov 4, 2026 |
About Marksans Pharma
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, an... [Read more]
Financial Performance
In fiscal year 2026, Marksans Pharma's revenue was 29.51 billion, an increase of 12.51% compared to the previous year's 26.23 billion. Earnings were 4.18 billion, an increase of 9.81%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MARKSANS stock is "Strong Buy." The 12-month stock price target is ₹324.33, which is an increase of 5.41% from the latest price.
News
Marksans Pharma Transcript: Q2 26/27
Record Q2 revenue reached INR 940 crore, up 30.5% YoY, while EBITDA rose 48.3% to INR 214 crore. Growth was broad-based, though higher freight and input costs temper the margin outlook; management targets INR 4,000 crore revenue next year.
Marksans Pharma Quarterly report: Q2 2027
Marksans Pharma has published its Q2 2027 quarterly earnings report on November 5, 2026.
Marksans Pharma Slides: Q2 2027
Marksans Pharma has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 5, 2026.
Marksans Pharma Transcript: Q1 26/27
Q1 FY27 revenue rose 35.6% YoY, with record EBITDA and PAT as Europe accelerated through organic growth and acquisitions. FY guidance was maintained, while management outlined further geographic expansion and selective M&A.
Marksans Pharma Quarterly report: Q1 2027
Marksans Pharma has published its Q1 2027 quarterly earnings report on August 13, 2026.
Marksans Pharma Slides: Q1 2027
Marksans Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 13, 2026.
Marksans Pharma to acquire ABCnow GmbH for €892,384
Marksans Pharma Limited has announced its acquisition of ABCnow GmbH, a Germany-based pharmaceutical company, for a total cash consideration of €892,384. This strategic acquisition aims to enhance Mar...
Marksans Pharma announces ₹0.90 per share final dividend for FY26
Marksans Pharma has announced a final dividend of ₹0.90 per equity share for the financial year ended 31 March 2026. This decision was made during the company's Board of Directors…
Marksans Pharma announces 90% final dividend ahead of AGM
Marksans Pharma has announced a final dividend of ₹0.90 per equity share for the financial year ended 31 March 2026, subject to approval at the upcoming Annual General Meeting (AGM).…
Marksans Pharma submits machine-readable financial results for March 2026
Marksans Pharma has addressed a compliance issue by submitting a machine-readable version of its financial results for the quarter and year ended March 31, 2026. This submission follows a notification...
Marksans Pharma launches campaign to prevent transfer of unclaimed dividends
Marksans Pharma has initiated a 'Saksham Niveshak' campaign to help shareholders claim unclaimed dividends and update KYC details. The campaign aims to prevent the transfer of unclaimed dividends to t...
Marksans Pharma completes acquisition of QliniQ B.V.
Marksans Pharma has successfully completed the acquisition of 100% share capital of QliniQ B.V., a company based in the Netherlands. This strategic move marks a significant expansion for Marksans Phar...
Marksans Pharma launches 'Saksham Niveshak' campaign to address unclaimed dividends
Marksans Pharma has initiated a 'Saksham Niveshak' campaign aimed at assisting shareholders in claiming unclaimed dividends from the financial year 2018-19 onwards. This initiative is in response to a...
Marksans Pharma to acquire Netherlands-based QliniQ B.V. to expand presence in European markets
Marksans Pharma Ltd has announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a Netherlands-based pharmaceutical company with established sales...
Marksans Pharma Transcript: Q4 25/26
Record FY 2026 results with net income above INR 3,000 crore, strong growth in North America, and margin expansion. Guidance targets INR 4,000 crore revenue by FY 2028, with robust product pipeline and ongoing M&A focus.
Marksans Pharma Quarterly report: Q4 2026
Marksans Pharma has published its Q4 2026 quarterly earnings report on May 27, 2026.
Marksans Pharma Slides: Q4 2026
Marksans Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 27, 2026.
Marksans Pharma Annual report: Q4 2026
Marksans Pharma has published its Q4 2026 annual report on May 27, 2026.
Marksans Pharma reports highest-ever revenue of Rs 3,033 crore for FY26
Marksans Pharma Ltd. has announced its financial results for the fiscal year ending March 31, 2026, achieving a record total income of ₹3,033 crore. This marks a 12.8% increase compared…
Marksans Pharma Q4 Results: Net profit jumps 64% as EBITDA margin expands sharply
Marksans Pharma reported a strong set of quarterly earnings for the March 2026 quarter, driven by healthy revenue growth and significant improvement in operating profitability. The company’s consolida...
Marksans Pharma receives USFDA approval for Benzonatate Capsules
Marksans Pharma Limited has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, available in 100 mg…
Pharma sector stocks rally sharply today, April 1: Marksans Pharma jumps 6%, Alembic gains 5.37%, Glenmark Pharma surge 4.30%
Indian pharma stocks showed broad-based gains in early trading on April 1, 2026. Many companies in the sector traded higher on both BSE and NSE, even as the broader market…
Pharma sector stocks today, Feb 9: Marksans Pharma up 5%, Shilpa Medicare jumps 6%, Glenmark rises 1.83%
The Indian pharma sector showed mixed intraday movements on February 9, 2026, amid broader market gains driven by positive global...
Marksans Pharma Transcript: Q3 25/26
Q3 FY26 saw record revenue and margin expansion, led by strong US growth and stabilization in the UK. The company remains debt-free, with robust cash reserves, and is targeting INR 4,000 crore revenue in 2-3 years, supported by a strong order book and ongoing expansion in Europe and Canada.
Marksans Pharma Quarterly report: Q3 2026
Marksans Pharma has published its Q3 2026 quarterly earnings report on February 6, 2026.